Astrazeneca Pharma India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 13, 2025, 12:52 am

Market Cap	20,243 Cr.
Current Price	8,120
High / Low	9,211/5,140
Stock P/E	121
Book Value	272
Dividend Yield	0.30 %
ROCE	31.1 %
ROE	22.9 %
Face Value	2.00
PEG Ratio	157.05

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Astrazeneca Pharma India Ltd

Competitors of Astrazeneca Pharma India Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	138 Cr.	98.3	247/84.3	20.0	36.5	0.00 %	18.0 %	15.5 %	10.0
MPS Pharmaa Ltd	5.03 Cr.	2.63	4.33/2.61		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	44.2 Cr.	59.6	94.9/44.5	15.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	27.1 Cr.	18.5	29.0/13.1	27.7	6.64	0.00 %	2.65 %	2.08 %	10.0
Industry Average	18,000.05 Cr	1,088.97		42.83	183.87	0.33%	15.88%	16.72%	6.19

All Competitor Stocks of Astrazeneca Pharma India Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	201	232	232	236	250	285	295	311	306	383	388	408	440
Expenses	186	194	204	195	213	225	228	258	291	334	349	355	363
Operating Profit	15	38	28	41	37	60	67	53	15	49	38	53	77
OPM %	7%	16%	12%	17%	15%	21%	23%	17%	5%	13%	10%	13%	17%
Other Income	5	4	4	7	7	-32	8	25	10	9	-49	8	-26
Interest	0	0	0	0	0	0	0	0	1	-0	0	0	0
Depreciation	4	4	5	3	4	4	4	4	4	4	4	9	9
Profit before tax	16	37	27	44	39	23	71	73	20	54	-15	51	42
Tax %	30%	24%	26%	26%	26%	26%	25%	29%	23%	27%	-22%	25%	27%
Net Profit	11	28	20	33	29	17	54	52	16	39	-12	38	31
EPS in Rs	4.57	11.19	8.06	13.02	11.72	6.91	21.54	20.95	6.32	15.79	-4.72	15.37	12.34

Last Updated: March 3, 2025, 5:29 pm

Below is a detailed analysis of the quarterly data for Astrazeneca Pharma India Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is 440.00 Cr.. The value appears strong and on an upward trend. It has increased from 408.00 Cr. (Sep 2024) to 440.00 Cr., marking an increase of 32.00 Cr..
For Expenses, as of Dec 2024, the value is 363.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 355.00 Cr. (Sep 2024) to 363.00 Cr., marking an increase of 8.00 Cr..
For Operating Profit, as of Dec 2024, the value is 77.00 Cr.. The value appears strong and on an upward trend. It has increased from 53.00 Cr. (Sep 2024) to 77.00 Cr., marking an increase of 24.00 Cr..
For OPM %, as of Dec 2024, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 13.00% (Sep 2024) to 17.00%, marking an increase of 4.00%.
For Other Income, as of Dec 2024, the value is -26.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Sep 2024) to -26.00 Cr., marking a decrease of 34.00 Cr..
For Interest, as of Dec 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
For Depreciation, as of Dec 2024, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 9.00 Cr..
For Profit before tax, as of Dec 2024, the value is 42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Sep 2024) to 42.00 Cr., marking a decrease of 9.00 Cr..
For Tax %, as of Dec 2024, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Sep 2024) to 27.00%, marking an increase of 2.00%.
For Net Profit, as of Dec 2024, the value is 31.00 Cr.. The value appears to be declining and may need further review. It has decreased from 38.00 Cr. (Sep 2024) to 31.00 Cr., marking a decrease of 7.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 12.34. The value appears to be declining and may need further review. It has decreased from 15.37 (Sep 2024) to 12.34, marking a decrease of 3.03.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: May 3, 2025, 3:09 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	390	474	517	564	544	571	728	832	814	806	1,003	1,296	1,619
Expenses	459	487	528	547	506	525	657	711	678	719	838	1,111	1,402
Operating Profit	-68	-13	-11	16	37	46	71	121	135	86	165	184	217
OPM %	-18%	-3%	-2%	3%	7%	8%	10%	15%	17%	11%	16%	14%	13%
Other Income	10	23	6	7	14	12	16	13	13	15	-14	51	-58
Interest	0	0	0	0	0	0	0	1	1	1	1	1	1
Depreciation	12	10	15	17	16	15	15	19	20	17	16	15	26
Profit before tax	-70	0	-21	6	36	44	73	114	127	83	134	220	132
Tax %	27%		0%	9%	44%	41%	25%	37%	27%	26%	26%	26%
Net Profit	-90	-1	-21	5	20	26	54	72	93	62	99	162	97
EPS in Rs	-35.81	-0.20	-8.34	2.10	8.02	10.36	21.78	28.88	37.32	24.64	39.72	64.60	38.78
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	3%	5%	41%	40%	37%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	98.89%	-2000.00%	123.81%	300.00%	30.00%	107.69%	33.33%	29.17%	-33.33%	59.68%	63.64%
Change in YoY Net Profit Growth (%)	0.00%	-2098.89%	2123.81%	176.19%	-270.00%	77.69%	-74.36%	-4.17%	-62.50%	93.01%	3.96%

Astrazeneca Pharma India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	11%
5 Years:	12%
3 Years:	17%
TTM:	35%

Compounded Profit Growth
10 Years:	27%
5 Years:	22%
3 Years:	18%
TTM:	5%

Stock Price CAGR
10 Years:	25%
5 Years:	22%
3 Years:	48%
1 Year:	53%

Return on Equity
10 Years:	17%
5 Years:	21%
3 Years:	20%
Last Year:	23%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:40 am

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	5	5	5	5	5	5	5	5	5	5	5	5	5
Reserves	95	167	146	151	218	242	296	359	451	506	584	707	674
Borrowings	0	0	0	0	0	0	0	12	12	9	7	5	17
Other Liabilities	206	244	261	247	193	214	261	330	306	337	389	362	545
Total Liabilities	306	416	412	403	415	461	562	706	775	857	985	1,078	1,241
Fixed Assets	25	94	101	97	87	75	75	72	81	74	69	67	69
CWIP	74	9	12	6	5	4	7	24	4	2	1	0	0
Investments	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	208	312	298	299	324	382	480	611	690	780	915	1,011	1,172
Total Assets	306	416	412	403	415	461	562	706	775	857	985	1,078	1,241

Below is a detailed analysis of the balance sheet data for Astrazeneca Pharma India Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.00 Cr..
For Reserves, as of Sep 2024, the value is ₹674.00 Cr.. The value appears to be declining and may need further review. It has decreased from 707.00 Cr. (Mar 2024) to ₹674.00 Cr., marking a decrease of 33.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹17.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5.00 Cr. (Mar 2024) to ₹17.00 Cr., marking an increase of 12.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹545.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 362.00 Cr. (Mar 2024) to ₹545.00 Cr., marking an increase of 183.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹1,241.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,078.00 Cr. (Mar 2024) to ₹1,241.00 Cr., marking an increase of 163.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹69.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2024) to ₹69.00 Cr., marking an increase of 2.00 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹1,172.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,011.00 Cr. (Mar 2024) to ₹1,172.00 Cr., marking an increase of 161.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹1,241.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,078.00 Cr. (Mar 2024) to ₹1,241.00 Cr., marking an increase of 163.00 Cr..

Notably, the Reserves (674.00 Cr.) exceed the Borrowings (17.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	-6	-1	-46	57	38	9	55	87	105	101	58	28
Cash from Investing Activity +	-16	-15	-19	-4	0	-9	4	-171	173	5	18	22
Cash from Financing Activity +	-10	86	0	-1	0	0	0	-6	-9	-9	-24	-44
Net Cash Flow	-32	71	-64	53	38	-1	59	-90	269	96	52	5

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-68.00	-13.00	-11.00	16.00	37.00	46.00	71.00	109.00	123.00	77.00	158.00	179.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	26	41	30	54	29	35	40	37	38	39	39	43
Inventory Days	202	210	157	141	121	229	186	197	198	164	193	140
Days Payable	214	241	203	174	184	257	266	251	221	223	231	121
Cash Conversion Cycle	14	10	-16	21	-34	7	-39	-17	15	-20	1	62
Working Capital Days	-56	-45	-15	-28	-36	-8	-14	-15	-15	-33	-17	20
ROCE %	-53%	-12%	-13%	4%	15%	19%	27%	34%	30%	16%	31%	31%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%
FIIs	2.38%	2.48%	2.49%	2.61%	2.70%	2.68%	2.69%	2.66%	2.73%	2.79%	2.90%	2.92%
DIIs	1.19%	1.30%	1.32%	1.42%	1.41%	1.91%	2.42%	2.76%	3.77%	4.99%	5.08%	5.21%
Public	21.43%	21.22%	21.19%	20.97%	20.88%	20.40%	19.89%	19.57%	18.50%	17.21%	17.02%	16.85%
No. of Shareholders	57,760	53,980	49,085	45,619	42,146	38,946	32,380	29,032	29,418	27,169	27,615	27,322

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Nippon India Small Cap Fund	645,850	0.93	427.33	645,850	2025-04-22 17:25:41	0%
Nippon India Pharma Fund	11,561	0.11	7.65	11,561	2025-04-22 17:25:41	0%
ICICI Prudential MNC Fund	5,667	0.24	3.75	5,667	2025-04-22 17:25:41	0%
ICICI Prudential S&P BSE 500 ETF	72	0.03	0.05	72	2025-04-22 17:25:41	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	64.60	39.70	24.60	37.30	28.90
Diluted EPS (Rs.)	64.60	39.70	24.60	37.30	28.90
Cash EPS (Rs.)	70.58	46.22	31.42	45.37	36.32
Book Value[Excl.RevalReserv]/Share (Rs.)	284.77	235.48	204.56	182.47	145.78
Book Value[Incl.RevalReserv]/Share (Rs.)	284.77	235.48	204.56	182.47	145.78
Dividend / Share (Rs.)	24.00	16.00	10.00	2.00	1.00
Revenue From Operations / Share (Rs.)	518.21	401.19	322.24	325.42	332.72
PBDIT / Share (Rs.)	87.70	76.49	40.38	59.32	53.48
PBIT / Share (Rs.)	81.72	69.98	33.60	51.27	46.04
PBT / Share (Rs.)	87.82	53.64	33.22	50.84	45.59
Net Profit / Share (Rs.)	64.60	39.72	24.64	37.32	28.88
PBDIT Margin (%)	16.92	19.06	12.52	18.22	16.07
PBIT Margin (%)	15.77	17.44	10.42	15.75	13.83
PBT Margin (%)	16.94	13.37	10.30	15.62	13.70
Net Profit Margin (%)	12.46	9.89	7.64	11.46	8.68
Return on Networth / Equity (%)	22.68	16.86	12.04	20.45	19.81
Return on Capital Employeed (%)	28.34	29.11	16.03	27.20	30.36
Return On Assets (%)	14.98	10.08	7.19	12.04	10.22
Asset Turnover Ratio (%)	1.26	1.09	0.98	1.10	1.31
Current Ratio (X)	2.61	2.18	2.12	2.04	1.66
Quick Ratio (X)	1.97	1.68	1.70	1.51	1.15
Inventory Turnover Ratio (X)	0.61	0.51	0.59	0.59	0.49
Dividend Payout Ratio (NP) (%)	24.76	20.14	8.11	5.35	3.46
Dividend Payout Ratio (CP) (%)	22.66	17.30	6.36	4.40	2.75
Earning Retention Ratio (%)	75.24	79.86	91.89	94.65	96.54
Cash Earning Retention Ratio (%)	77.34	82.70	93.64	95.60	97.25
Interest Coverage Ratio (X)	182.71	303.52	106.25	136.06	117.27
Interest Coverage Ratio (Post Tax) (X)	121.90	222.46	65.84	86.60	64.34
Enterprise Value (Cr.)	12795.16	7617.77	5940.17	7173.15	5726.36
EV / Net Operating Revenue (X)	9.88	7.60	7.37	8.82	6.88
EV / EBITDA (X)	58.36	39.84	58.85	48.37	42.83
MarketCap / Net Operating Revenue (X)	10.27	8.09	7.93	9.25	7.19
Retention Ratios (%)	75.23	79.85	91.88	94.64	96.53
Price / BV (X)	18.68	13.79	12.49	16.50	16.41
Price / Net Operating Revenue (X)	10.27	8.09	7.93	9.25	7.19
EarningsYield	0.01	0.01	0.01	0.01	0.01

After reviewing the key financial ratios for Astrazeneca Pharma India Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 24, the value is 64.60. This value is within the healthy range. It has increased from 39.70 (Mar 23) to 64.60, marking an increase of 24.90.
For Diluted EPS (Rs.), as of Mar 24, the value is 64.60. This value is within the healthy range. It has increased from 39.70 (Mar 23) to 64.60, marking an increase of 24.90.
For Cash EPS (Rs.), as of Mar 24, the value is 70.58. This value is within the healthy range. It has increased from 46.22 (Mar 23) to 70.58, marking an increase of 24.36.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 284.77. It has increased from 235.48 (Mar 23) to 284.77, marking an increase of 49.29.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 284.77. It has increased from 235.48 (Mar 23) to 284.77, marking an increase of 49.29.
For Dividend / Share (Rs.), as of Mar 24, the value is 24.00. This value exceeds the healthy maximum of 3. It has increased from 16.00 (Mar 23) to 24.00, marking an increase of 8.00.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 518.21. It has increased from 401.19 (Mar 23) to 518.21, marking an increase of 117.02.
For PBDIT / Share (Rs.), as of Mar 24, the value is 87.70. This value is within the healthy range. It has increased from 76.49 (Mar 23) to 87.70, marking an increase of 11.21.
For PBIT / Share (Rs.), as of Mar 24, the value is 81.72. This value is within the healthy range. It has increased from 69.98 (Mar 23) to 81.72, marking an increase of 11.74.
For PBT / Share (Rs.), as of Mar 24, the value is 87.82. This value is within the healthy range. It has increased from 53.64 (Mar 23) to 87.82, marking an increase of 34.18.
For Net Profit / Share (Rs.), as of Mar 24, the value is 64.60. This value is within the healthy range. It has increased from 39.72 (Mar 23) to 64.60, marking an increase of 24.88.
For PBDIT Margin (%), as of Mar 24, the value is 16.92. This value is within the healthy range. It has decreased from 19.06 (Mar 23) to 16.92, marking a decrease of 2.14.
For PBIT Margin (%), as of Mar 24, the value is 15.77. This value is within the healthy range. It has decreased from 17.44 (Mar 23) to 15.77, marking a decrease of 1.67.
For PBT Margin (%), as of Mar 24, the value is 16.94. This value is within the healthy range. It has increased from 13.37 (Mar 23) to 16.94, marking an increase of 3.57.
For Net Profit Margin (%), as of Mar 24, the value is 12.46. This value exceeds the healthy maximum of 10. It has increased from 9.89 (Mar 23) to 12.46, marking an increase of 2.57.
For Return on Networth / Equity (%), as of Mar 24, the value is 22.68. This value is within the healthy range. It has increased from 16.86 (Mar 23) to 22.68, marking an increase of 5.82.
For Return on Capital Employeed (%), as of Mar 24, the value is 28.34. This value is within the healthy range. It has decreased from 29.11 (Mar 23) to 28.34, marking a decrease of 0.77.
For Return On Assets (%), as of Mar 24, the value is 14.98. This value is within the healthy range. It has increased from 10.08 (Mar 23) to 14.98, marking an increase of 4.90.
For Asset Turnover Ratio (%), as of Mar 24, the value is 1.26. It has increased from 1.09 (Mar 23) to 1.26, marking an increase of 0.17.
For Current Ratio (X), as of Mar 24, the value is 2.61. This value is within the healthy range. It has increased from 2.18 (Mar 23) to 2.61, marking an increase of 0.43.
For Quick Ratio (X), as of Mar 24, the value is 1.97. This value is within the healthy range. It has increased from 1.68 (Mar 23) to 1.97, marking an increase of 0.29.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.61. This value is below the healthy minimum of 4. It has increased from 0.51 (Mar 23) to 0.61, marking an increase of 0.10.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 24.76. This value is within the healthy range. It has increased from 20.14 (Mar 23) to 24.76, marking an increase of 4.62.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 22.66. This value is within the healthy range. It has increased from 17.30 (Mar 23) to 22.66, marking an increase of 5.36.
For Earning Retention Ratio (%), as of Mar 24, the value is 75.24. This value exceeds the healthy maximum of 70. It has decreased from 79.86 (Mar 23) to 75.24, marking a decrease of 4.62.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 77.34. This value exceeds the healthy maximum of 70. It has decreased from 82.70 (Mar 23) to 77.34, marking a decrease of 5.36.
For Interest Coverage Ratio (X), as of Mar 24, the value is 182.71. This value is within the healthy range. It has decreased from 303.52 (Mar 23) to 182.71, marking a decrease of 120.81.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 121.90. This value is within the healthy range. It has decreased from 222.46 (Mar 23) to 121.90, marking a decrease of 100.56.
For Enterprise Value (Cr.), as of Mar 24, the value is 12,795.16. It has increased from 7,617.77 (Mar 23) to 12,795.16, marking an increase of 5,177.39.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 9.88. This value exceeds the healthy maximum of 3. It has increased from 7.60 (Mar 23) to 9.88, marking an increase of 2.28.
For EV / EBITDA (X), as of Mar 24, the value is 58.36. This value exceeds the healthy maximum of 15. It has increased from 39.84 (Mar 23) to 58.36, marking an increase of 18.52.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 10.27. This value exceeds the healthy maximum of 3. It has increased from 8.09 (Mar 23) to 10.27, marking an increase of 2.18.
For Retention Ratios (%), as of Mar 24, the value is 75.23. This value exceeds the healthy maximum of 70. It has decreased from 79.85 (Mar 23) to 75.23, marking a decrease of 4.62.
For Price / BV (X), as of Mar 24, the value is 18.68. This value exceeds the healthy maximum of 3. It has increased from 13.79 (Mar 23) to 18.68, marking an increase of 4.89.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 10.27. This value exceeds the healthy maximum of 3. It has increased from 8.09 (Mar 23) to 10.27, marking an increase of 2.18.
For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Astrazeneca Pharma India Ltd as of May 12, 2025 is: 6,047.57

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of May 12, 2025, Astrazeneca Pharma India Ltd is Overvalued by 25.52% compared to the current share price 8,120.00

Intrinsic Value of Astrazeneca Pharma India Ltd as of May 12, 2025 is: 6,094.16

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of May 12, 2025, Astrazeneca Pharma India Ltd is Overvalued by 24.95% compared to the current share price 8,120.00

Last 5 Year EPS CAGR: 0.77%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a low average Working Capital Days of -21.83, which is a positive sign. The company has higher reserves (353.54 cr) compared to borrowings (4.77 cr), indicating strong financial stability. The company has shown consistent growth in sales (480.23 cr) and profit (67.54 cr) over the years.	The stock has a low average ROCE of 10.75%, which may not be favorable. The stock has a high average Cash Conversion Cycle of 0.33, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astrazeneca Pharma India Ltd:
1. Net Profit Margin: 12.46%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 28.34% (Industry Average ROCE: 15.75%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 22.68% (Industry Average ROE: 16.17%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 121.9
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.97
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 121 (Industry average Stock P/E: 34.05)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

AstraZeneca Pharma India Ltd. is a Public Limited Listed company incorporated on 11/07/1979 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L24231KA1979PLC003563 and registration number is 003563. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1295.53 Cr. and Equity Capital is Rs. 5.00 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Block N1, 12th Floor, Bengaluru Karnataka 560045	comp.secy@astrazeneca.com http://www.astrazeneca.com/india

Management
Name	Position Held
Mr. Narayan K Seshadri	Chairperson & Independent Director
Mr. Sanjeev Kumar Panchal	Executive Director
Ms. Bhavana Agrawal	Executive Director
Ms. Sylvia Lorena Varela Ramon	Non Executive Director
Ms. Hooi Bien Chuah	Non Executive Director
Ms. Shilpa Divekar Nirula	Independent Director
Ms. Revathy Ashok	Independent Director

FAQ

What is the intrinsic value of Astrazeneca Pharma India Ltd?

Astrazeneca Pharma India Ltd's intrinsic value (as of 12 May 2025) is ₹6047.57 — 25.52% lower the current market price of 8,120.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 20,243 Cr. market cap, FY2025-2026 high/low of ₹9,211/5,140, reserves of 674 Cr, and liabilities of 1,241 Cr.

What is the Market Cap of Astrazeneca Pharma India Ltd?

The Market Cap of Astrazeneca Pharma India Ltd is 20,243 Cr..

What is the current Stock Price of Astrazeneca Pharma India Ltd as on 12 May 2025?

The current stock price of Astrazeneca Pharma India Ltd as on 12 May 2025 is 8,120.

What is the High / Low of Astrazeneca Pharma India Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Astrazeneca Pharma India Ltd stocks is ₹9,211/5,140.

What is the Stock P/E of Astrazeneca Pharma India Ltd?

The Stock P/E of Astrazeneca Pharma India Ltd is 121.

What is the Book Value of Astrazeneca Pharma India Ltd?

The Book Value of Astrazeneca Pharma India Ltd is 272.

What is the Dividend Yield of Astrazeneca Pharma India Ltd?

The Dividend Yield of Astrazeneca Pharma India Ltd is 0.30 %.

What is the ROCE of Astrazeneca Pharma India Ltd?

The ROCE of Astrazeneca Pharma India Ltd is 31.1 %.

What is the ROE of Astrazeneca Pharma India Ltd?

The ROE of Astrazeneca Pharma India Ltd is 22.9 %.

What is the Face Value of Astrazeneca Pharma India Ltd?

The Face Value of Astrazeneca Pharma India Ltd is 2.00.